Inflammatory bowel disease: towards a personalized medicine.

about

A Noninvasive Method to Assess Mucosal Healing in Patients* With Crohn’s Disease.Proteomics and Lipidomics in Inflammatory Bowel Disease Research: From Mechanistic Insights to Biomarker Identification

P2860

Q55512054-034D61C9-5950-4056-A84D-D771CDDF4737 Q57156865-F6858121-1709-429D-8FF2-F3C930FD45BC

P2860

Inflammatory bowel disease: towards a personalized medicine.

Item

http://www.wikidata.org/entity/Q49570157

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Inflammatory bowel disease: towards a personalized medicine.

@en

Inflammatory bowel disease: towards a personalized medicine.

@nl

type

Item

label

Inflammatory bowel disease: towards a personalized medicine.

@en

Inflammatory bowel disease: towards a personalized medicine.

@nl

prefLabel

Inflammatory bowel disease: towards a personalized medicine.

@en

Inflammatory bowel disease: towards a personalized medicine.

@nl

P1476

Inflammatory bowel disease: towards a personalized medicine

@en

P2093

Mathurin Flamant

http://www.w3.org/2001/XMLSchema#string

P2860

New serological markers in inflammatory bowel disease are associated with complicated disease behaviour

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Infliximab for induction and maintenance therapy for ulcerative colitis

Guided self-management and patient-directed follow-up of ulcerative colitis: a randomised trial.

Effect upon hospital activity of the application of a continued care model centered on patients with inflammatory bowel disease.

Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial.

Microscopic activity in ulcerative colitis: what does it mean?

A randomized trial comparing telemedicine case management with usual care in older, ethnically diverse, medically underserved patients with diabetes mellitus

Predicting response to Anti-TNF Agents for the treatment of crohn's disease.

Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial.

P304

1756283X17745029

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1756283X17745029

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

X Roblin

P577

2018-01-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29383027

http://www.w3.org/2001/XMLSchema#string

P921

inflammatory bowel diseases

P932

5784543

http://www.w3.org/2001/XMLSchema#string

Inflammatory bowel disease: towards a personalized medicine.

about

P2860

P2860

Inflammatory bowel disease: towards a personalized medicine.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P921

P932